FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to biotechnology and medicine. Administering into an individual a nucleic acid molecule, which is able to bind to MCP-1 and is an MCP-1 antagonist, wherein the nucleic acid molecule contains the nucleic acid sequence SEQ ID NO:37 in a combination with an immunosuppressive agent, for treating lupus nephritis enables reducing a dose of the immunosuppressive agent.
EFFECT: administering into the individual the nucleic acid molecule, wherein the nucleic acid molecule contains the nucleic acid sequence SEQ ID NO:37 has a therapeutic effect in treating pulmonary hypertension and chronic obstructive pulmonary disease.
30 cl, 54 dwg, 1 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MCP-1 BINDING NUCLEIC ACIDS | 2007 |
|
RU2518330C2 |
| SDF-1 BINDING NUCLEIC ACIDS AND USE THEREOF | 2008 |
|
RU2612388C2 |
| SDF-1 BINDING NUCLEIC ACIDS | 2007 |
|
RU2590709C2 |
| SDF1-BINDING NUCLEIC ACIDS AND USE THEREOF IN CANCER TREATMENT | 2011 |
|
RU2679495C2 |
| NEW CONNECTING C5a NUCLEIC ACIDS | 2013 |
|
RU2645261C2 |
| METHOD FOR POLYALKOXYLATING NUCLEIC ACIDS, ALLOWING FOR EXTRACTION AND REUSE OF EXCESS POLYALKOXYLATING REAGENT | 2017 |
|
RU2765027C2 |
| OLIGONUCLEOTIDE SEQUENCES AIMED AT THE TRANSCRIPTION FACTOR TSC22D4, FOR TREATING INSULIN RESISTANCE | 2016 |
|
RU2723091C2 |
| MEANS FOR INHIBITING PROTEINKINASE 3 EXPRESSION | 2007 |
|
RU2553561C2 |
| COMPLEMENT-BINDING APTAMERS AND C5 AGENTS APPLICABLE FOR TREATING OCULAR DISORDERS | 2007 |
|
RU2477137C2 |
| SINGLE-STRANDED NUCLEIC ACID MOLECULE INHIBITING EXPRESSION OF PRORENIN GENE OR PRORENIN RECEPTOR GENE, AND USE THEREOF | 2016 |
|
RU2718984C2 |
